0.7217
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.7249
Aprire:
$0.716
Volume 24 ore:
614.34K
Relative Volume:
0.37
Capitalizzazione di mercato:
$23.95M
Reddito:
-
Utile/perdita netta:
$-98.79M
Rapporto P/E:
-0.2207
EPS:
-3.27
Flusso di cassa netto:
$-51.66M
1 W Prestazione:
+17.35%
1M Prestazione:
+154.03%
6M Prestazione:
-76.10%
1 anno Prestazione:
-75.37%
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Nome
Relmada Therapeutics Inc
Settore
Industria
Telefono
646 876 3459
Indirizzo
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Confronta RLMD con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
3.03 | 0 | 0 | 0 | 0 | 0.00 | |
![]()
GOODO
Gladstone Commercial Corporation
|
20.34 | 372.90M | 0 | 0 | 0 | 0.00 |
![]()
JUNE
Dhandho Junoon Etf
|
10.80 | 210.86M | 0 | 0 | 0 | 0.00 |
![]()
SHMD
Schmid Group N V
|
2.98 | 128.54M | 0 | 0 | 0 | 0.00 |
![]()
PSNYW
Polestar Automotive Holding Uk
|
0.16 | 350.11M | 2.07B | -1.42B | -1.37B | -0.6765 |
![]()
MOBBW
Mobilicom Limited Warrants
|
0.34 | 398.00M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-05 | Downgrade | Mizuho | Outperform → Neutral |
2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
2024-06-05 | Downgrade | Goldman | Neutral → Sell |
2022-10-14 | Downgrade | Goldman | Buy → Neutral |
2022-10-14 | Downgrade | Guggenheim | Buy → Neutral |
2022-10-14 | Downgrade | Truist | Buy → Hold |
2022-10-13 | Downgrade | Oppenheimer | Outperform → Perform |
2021-11-18 | Iniziato | Mizuho | Buy |
2021-05-20 | Ripresa | Goldman | Buy |
2020-10-28 | Downgrade | Goldman | Buy → Neutral |
2020-07-14 | Iniziato | Oppenheimer | Outperform |
2020-05-04 | Iniziato | SunTrust | Buy |
2020-04-21 | Iniziato | Goldman | Buy |
2020-01-27 | Iniziato | Jefferies | Buy |
2020-01-10 | Iniziato | SVB Leerink | Outperform |
2019-12-16 | Iniziato | Guggenheim | Buy |
Mostra tutto
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
Relmada Therapeutics Holds Annual Stockholders Meeting - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Relmada Therapeutics (NASDAQ:RLMD) Lowered to Strong Sell Rating by Wall Street Zen - Defense World
RELMADA THERAPEUTICS Executives Make Significant Stock Purchases in May 2025 - TradingView
Relmada Therapeutics Executives Make Bold Stock Purchases! - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Relmada Therapeutics (RLMD) and Roivant Sciences (ROIV) - The Globe and Mail
Relmada Therapeutics’ Earnings Call: Promising Data Amid Financial Concerns - TipRanks
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Relmada Therapeutics’ Q1 2025 results miss EPS expectations - Investing.com
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights: Promising Pipeline ... - Yahoo Finance
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Relmada Therapeutics Inc (RLMD) Q1 2025 Earnings Call Highlights - GuruFocus
Relmada Therapeutics Reports Q1 2025 Financial Results - TipRanks
Transcript : Relmada Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Relmada Therapeutics to Report First Quarter 2025 Financial Resu - GuruFocus
Relmada Therapeutics (RLMD) Expected to Announce Earnings on Monday - Defense World
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - The Manila Times
Relmada Therapeutics, Inc. Announces Conference Call to Discuss Q1 2025 Financial Results and Business Progress - Nasdaq
Renaissance Technologies LLC Buys 138,625 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) - Defense World
Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com
It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX
Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - EIN News
Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com
Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada
Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com
SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow
Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider
Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan
Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus
Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus
Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times
Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News
RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Relmada Therapeutics Inc (RLMD) receives a Neutral rating from Mizuho - knoxdaily.com
RLMD Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 0.8% – Should You Sell? - Defense World
Relmada Therapeutics Inc Azioni (RLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):